CTD110.6 monoclonal antibody

O-linked N-acetylglucosamine (O-GlcNAc) is a newly described but ubiquitous dynamic modification of key regulatory proteins in side virtually all multi-cellular eukaryotic cells. Recently, this sugar modification has been shown to be as abundant as protein phosphorylation, often competing with this key regulatory switch in the cell?s regulatory pathways. O-GlcNAc is now implicated to play an important role in diabetes, cancer and neurodegenerative diseases, such as Alzheimer?s Disease. The monoclonal antibody CTD110.6 is a valuable tool for the study of O-GlcNAc. This antibody specifically recognizes the modification on a wide variety of proteins in a manner that is analogous to the widely used antibodies to protein phosphorylation. Description (Set) Proposed Use (Set) Researchers interested in transcription, diabetes, tumor suppressors , oncogenes or cytoskeletal proteins. Potentially useful as a diagnositic tool, especially in diabetes and Alzhemer?s Disease.

Inventor(s): Hart, Gerald W.

Type of Offer: Licensing



« More Medical Patents

---